Phase III AIRTIVITY study design: verducatib (BI 1291583) in people with bronchiectasis

ERJ Open Research 2026 Open access

Read full text
Authors: James D. Chalmers, Michal Shteinberg, Sanjay Haresh Chotirmall, Wiebke Sauter, Patrick A. Flume, Raksha Jain, Kozo Morimoto, Anne E. O'Donnell, Felix C. Ringshausen, Henrik Watz, Jin‐Fu Xu, Johanna Rauch
+8 more Anastasia Eleftheraki, Annemarie T. Engel, Anne B. Chang, Kim G. Nielsen, Giselle Benitez, Abhya Gupta, Marcus Alexander Mall, Pamela J. McShane
DOI: 10.1183/23120541.01068-2025
Cited by: 1
References: 40

Abstract

There is an unmet need for therapies targeting chronic neutrophilic inflammation in bronchiectasis. In the phase II, dose-finding AIRLEAF study, the dipeptidyl peptidase 1 (cathepsin C) inhibitor verducatib (BI 1291583) reduced the pulmonary exacerbation risk in people with bronchiectasis and demonstrated a similar safety profile to placebo; these results support the investigation of verducatib in a phase III study. Here, we describe the design of the randomised, placebo-controlled phase III AIRTIVITY study ( ClinicalTrials.gov identifier NCT06872892 ), assessing the efficacy, safety and tolerability of verducatib in people with bronchiectasis. In AIRTIVITY, approximately 1680 adults and 75 adolescents (aged 12–

Fields of Study & Subjects

Cystic Fibrosis Research Advances Neonatal Respiratory Health Research Chronic Obstructive Pulmonary Disease (COPD) Research

Publication details

Journal / source
ERJ Open Research
Publisher
European Respiratory Society (ERS)
Volume
12
Issue
5
Pages
01068–2025
Publication date
23 April 2026
Language
EN